Ever since Anavex Life Sciences Corp (OTCMKTS:AVXL) revealed the data of a new report, its share price has been posting strong gains remarkably. However, it consolidated in last trading session and closed at $0.379. The decline of 0.26% came at a share volume of 2.30 compared to average share volume of 1.80 million.
The most significant press release by Anavex was issued during late April when it highlighted the review on its Sigma-1 receptor agonists. The review and data appeared in a Scientific Journal known as Neuroscience Letters.
The publication highlighted the real-time trial data which demonstrated the success of sigma-1 receptor in overcoming the harmful effects of microglial inflammation. As per report, after sigma-1 receptor gets activated, it helps in mitigating the negative response caused by Chronic Microglia. The excess of Microglia can result in a number of harmful neurodegenerative diseases.
The company said that the findings highlighted in the journal were promising and helped establish the base that the sigma-1 receptor possesses power to restrict harmful impact of Chronic Microglia. The review published in the Scientific Journal further indicates the prominent role of Anavex Life lead candidates sigma-1 receptor agonists, particularly ANAVEX 2-73. As of now it is under a Phase II a clinical trial to treat Alzheimer’s disease. Anavex concluded important points from the article that sigma-1 receptor activity could be increased through agonists. It can help to nullify the negative impact of neuro inflammation.
The encouraging results
Anavex found the report data convincing to drive a conclusion that activating sigma-1 receptor have0 a lot of importance in controlling the problems associated with Chronic Microglia. The company’s Chief Executive Christopher U. Missling expressed optimism over the data and was confident that company’s drug ANAVEX 2-73 will successfully reduce negative impact of microglia inflammation.